Search research articles
Contact Us
Filters
Showing results (181-190 of 232) with videos related to
Page
of 24
Sort By:
Investigational New Drugs
|
May 3, 2014
A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients
Anna Spreafico, Kim N Chi, Srikala S Sridhar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 16, 2003
Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study
Chris H Takimoto, Scot C Remick, Sunil Sharma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 3, 2007
Inflammatory breast cancer as a model disease to study tumor angiogenesis: results of a phase IB trial of combination SU5416 and doxorubicin
Beth Overmoyer, Pingfu Fu, Charles Hoppel, et al.
Investigational New Drugs
|
August 1, 2012
A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors
Amir Mortazavi, Yonghua Ling, Ludmila Katherine Martin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 14, 2025
Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials
Jia Liu, Max Farrow, Lesley Seymour, et al.
Breast Cancer Research and Treatment
|
February 28, 2023
A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620)
Monica K Malhotra, Shalu Pahuja, Brian F Kiesel, et al.
NPJ Precision Oncology
|
December 5, 2017
Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival
Ovidiu C Andronesi, Morteza Esmaeili, Ronald J H Borra, et al.
Cancer Chemotherapy and Pharmacology
|
October 23, 2020
Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors
Khanh T Do, Geraldine O'Sullivan Coyne, John L Hays, et al.
The Lancet. Oncology
|
September 15, 2014
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
Joyce F Liu, William T Barry, Michael Birrer, et al.
Neuro-Oncology
|
July 6, 2013
Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma
Christine Lu-Emerson, Matija Snuderl, Nathaniel D Kirkpatrick, et al.
Page
of 24
Search research articles
Search
Showing results (181-190 of 232) with videos related to
Sort By:
Page
of 24
Investigational New Drugs
|
May 3, 2014
A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients
Anna Spreafico, Kim N Chi, Srikala S Sridhar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 16, 2003
Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study
Chris H Takimoto, Scot C Remick, Sunil Sharma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 3, 2007
Inflammatory breast cancer as a model disease to study tumor angiogenesis: results of a phase IB trial of combination SU5416 and doxorubicin
Beth Overmoyer, Pingfu Fu, Charles Hoppel, et al.
Investigational New Drugs
|
August 1, 2012
A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors
Amir Mortazavi, Yonghua Ling, Ludmila Katherine Martin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 14, 2025
Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials
Jia Liu, Max Farrow, Lesley Seymour, et al.
Breast Cancer Research and Treatment
|
February 28, 2023
A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620)
Monica K Malhotra, Shalu Pahuja, Brian F Kiesel, et al.
NPJ Precision Oncology
|
December 5, 2017
Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival
Ovidiu C Andronesi, Morteza Esmaeili, Ronald J H Borra, et al.
Cancer Chemotherapy and Pharmacology
|
October 23, 2020
Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors
Khanh T Do, Geraldine O'Sullivan Coyne, John L Hays, et al.
The Lancet. Oncology
|
September 15, 2014
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
Joyce F Liu, William T Barry, Michael Birrer, et al.
Neuro-Oncology
|
July 6, 2013
Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma
Christine Lu-Emerson, Matija Snuderl, Nathaniel D Kirkpatrick, et al.
Page
of 24